Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia

Area of Science:

• Hematology
• Pediatric Oncology
• Cancer Genetics

Background:

• Pediatric acute lymphoblastic leukemia (pALL) is the most common childhood cancer, with current survival rates of 80-90%.
• Improving supportive care and tailoring treatments based on relapse risk, particularly genetic features of malignant cells, are key priorities.
• Advances include classifying pALL subgroups by genetic characteristics like aneuploidy or translocation to align with treatment response.

Approach:

• This review summarizes current treatment strategies for pALL.
• Focuses on therapies targeting tyrosine kinases and various signaling pathways.
• Includes BCL inhibitors and anti-cluster differentiation (anti-CD) therapy.

Key Points:

• Genetic alterations in pALL pathogenesis involve transcription regulators (e.g., PAX5, IKZF1), coactivators (e.g., TBL1XR1, ERG), lymphoid signaling molecules (e.g., BTLA, CD200 TOX), and tumor suppressor genes (e.g., CDKN2A, TP53).
• Current research is exploring CAR T-cell therapy (chimeric antigen receptors T-cell therapy) for pALL, though further development is needed.
• Treatment strategies are increasingly informed by the genetic landscape of the leukemia.

Conclusions:

• Personalized treatment strategies based on genetic profiling are crucial for optimizing outcomes in pediatric ALL.
• Targeted therapies, including tyrosine kinase inhibitors and BCL inhibitors, show promise.
• CAR T-cell therapy represents a promising avenue for future pALL treatment research.